
Predicine BEACONTM

Introducing Next-Generation Actionable MRD


An ultra-sensitive Minimal Residual Disease (MRD) detection that is not limited by baseline tissue sample availability.



Methods and Reporting

- Flexibility in baseline profiling tissue or liquid biopsy
- Ultra-sensitive in MRD detection 0.005% LOD
- Includes genome-wide copy number changes
- Longitudinally tracks up to 50 personalized mutations
- Includes analysis of 500 actionable approved therapy selection mutations

Workflow



PredicineBEACON addresses the challenges faced by conventional MRD assays

- Baseline agnostic solution: Baseline analysis can be obtained via blood, urine, or tissue
- Ultra-sensitive: Ability to identify alterations missed by less sensitive assays
- Multi-dimentional: Detects all types of DNA changes, including fusion and copy number changes
- Actionable MRD result: Upon recurrence, actionable mutation analysis will provide treatment insights

Predicine


Predicine **BEACON**TM

Introducing Next-Generation Actionable MRD

Product details



MRD Detection Unbounded by Baseline Sample Availability



MRD detection with PredicineBEACON™ is not limited by baseline tissue sample availability. If available, baseline samples can be assessed using patient's blood, urine or tissue. Monitoring recurrence or progression of cancer can be achieved with a simple blood draw or urine sample. Monitoring intervals can be customized according to risk or medical necessity.

Contact Us:

support.us@predicine.com | (877) 752-3958 3555 Arden Rd, Hayward, CA 94545 www.predicine.com

Learn More:

Visit: www.predicine.com/predicinebeacon

